NASDAQ Framework: Tempus AI Inc.
Healthcare technology company specializing in AI diagnostics 1.
1: Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois. View Source
Tempus AI, Inc. is a healthcare technology company that leverages artificial intelligence to provide next-generation sequencing diagnostics, molecular genotyping, and other advanced pathology testing services to healthcare providers, pharmaceutical companies, and researchers 2. The company has developed a comprehensive platform that integrates clinical, molecular, and imaging data to deliver highly personalized treatment options 3. Tempus AI has amassed one of the largest libraries of clinical and molecular oncology data in the world, facilitating the discovery, development, and delivery of optimal therapeutics 4. The company has also launched various AI-enabled products and services, including the Tempus One clinical assistant and multimodal immune profile algorithmic tests 56. Founded in 2015 and headquartered in Chicago, Illinois, Tempus AI continues to expand its market presence and innovation in precision medicine 78.
2: Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois. View Source3: Michael Ryskin has given his Buy rating due to a combination of factors surrounding Tempus AI, Inc. Class A’s innovative approach to healthcare. Tempus AI leverages artificial intelligence to integrate molecular diagnostics with a patient’s clinical and imaging data, providing highly personalized treatment options. This AI-enabled precision medicine represents a significant advancement in healthcare, making the company’s services attractive to both patients and biopharmaceutical partners. Ryskin acknowledges Tempus AI’s substantial market potential, noting the company’s impressive reach into a large addressable market, which is estimated to be at least $70 billion. Additionally, Tempus AI has demonstrated rapid scale, forecasting sales in excess of $500 million for 2023 with a future growth rate of over 20%. View Source4: Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. View Source5: Tempus announced the broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips. View Source6: Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests View Source7: Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois. View Source8: Tempus AI, which provides data and analytics tools for precision medicine, filed on Monday with the SEC to raise up to $100 million in an initial public offering. However, the deal size is likely a placeholder for an IPO that we estimate could raise $600 million. Tempus is focused on unlocking the power of precision medicine through the practical application of artificial intelligence in healthcare, resulting in the creation of its Tempus Platform. The platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions through approximately 450 unique data connections across more than 2,000 healthcare institutions. This proprietary technology has allowed Tempus to amass what it considers to be one of the largest libraries of clinical and molecular oncology data in the world.The Chicago, IL-based company was founded in 2015 and booked $562 million in revenue for the 12 months ended March 31, 2024. It plans to list on the Nasdaq under the symbol TEM. Tempus AI filed confidentially on September 1, 2021. The company was previously known as Tempus Labs until it rebranded as Tempus AI in December 2023. Morgan Stanley, J.P. Morgan, Allen & Company, BofA Securities, TD Cowen, Stifel, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed. View Source
UNKNOWN
The provided facts do not specify whether the founders of Tempus AI Inc. are still leading the company or are heavily involved in its operations.
The provided facts do not specify whether the founders of Tempus AI Inc. are still leading the company or are heavily involved in its operations.
LOW RISK
Tempus AI, Inc. demonstrates a robust financial profile with significant revenue generation and growth potential. The company booked $562 million in revenue for the 12 months ended March 31, 2024 9, and it forecasts sales in excess of $500 million for 2023 with a future growth rate of over 20% 10. Additionally, Tempus AI successfully raised $410.7 million through its initial public offering 11, further strengthening its financial position. These factors, combined with its innovative AI-driven healthcare solutions and substantial market potential, suggest that Tempus AI is well-positioned to cover its costs and spending plans, indicating a low financial risk.
Tempus AI, Inc. demonstrates a robust financial profile with significant revenue generation and growth potential. The company booked $562 million in revenue for the 12 months ended March 31, 2024 9, and it forecasts sales in excess of $500 million for 2023 with a future growth rate of over 20% 10. Additionally, Tempus AI successfully raised $410.7 million through its initial public offering 11, further strengthening its financial position. These factors, combined with its innovative AI-driven healthcare solutions and substantial market potential, suggest that Tempus AI is well-positioned to cover its costs and spending plans, indicating a low financial risk.
9: Tempus AI, which provides data and analytics tools for precision medicine, filed on Monday with the SEC to raise up to $100 million in an initial public offering. However, the deal size is likely a placeholder for an IPO that we estimate could raise $600 million. Tempus is focused on unlocking the power of precision medicine through the practical application of artificial intelligence in healthcare, resulting in the creation of its Tempus Platform. The platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions through approximately 450 unique data connections across more than 2,000 healthcare institutions. This proprietary technology has allowed Tempus to amass what it considers to be one of the largest libraries of clinical and molecular oncology data in the world.The Chicago, IL-based company was founded in 2015 and booked $562 million in revenue for the 12 months ended March 31, 2024. It plans to list on the Nasdaq under the symbol TEM. Tempus AI filed confidentially on September 1, 2021. The company was previously known as Tempus Labs until it rebranded as Tempus AI in December 2023. Morgan Stanley, J.P. Morgan, Allen & Company, BofA Securities, TD Cowen, Stifel, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed. View Source10: Michael Ryskin has given his Buy rating due to a combination of factors surrounding Tempus AI, Inc. Class A’s innovative approach to healthcare. Tempus AI leverages artificial intelligence to integrate molecular diagnostics with a patient’s clinical and imaging data, providing highly personalized treatment options. This AI-enabled precision medicine represents a significant advancement in healthcare, making the company’s services attractive to both patients and biopharmaceutical partners. Ryskin acknowledges Tempus AI’s substantial market potential, noting the company’s impressive reach into a large addressable market, which is estimated to be at least $70 billion. Additionally, Tempus AI has demonstrated rapid scale, forecasting sales in excess of $500 million for 2023 with a future growth rate of over 20%. View Source11: Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 per share. All of the shares of Class A common stock are being offered by Tempus. The gross proceeds to Tempus from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tempus, are expected to be $410.7 million. In addition, Tempus has granted the underwriters a 30-day option to purchase up to an additional 1,665,000 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. View Source
12: Tempus announced the broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips. View Source13: Tempus AI launches AI-enabled, multimodal immune profile algorithmic testsJuly 16, 2024TipRanksLargest borrow rate increases among liquid namesJuly 15, 2024TipRanksBuy/Sell: Wall Street’s top 10 stock calls this weekJuly 12, 2024TipRanksTempus AI surpasses 500 research publicationsJuly 10, 2024TipRanksTempus AI initiated, Helios downgraded: Wall Street’s top analyst callsJuly 9, 2024TipRanks View Source
Tempus AI Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through to 2026, focusing on leveraging its AI-driven precision medicine platform to introduce new and innovative healthcare solutions. The company plans to expand its portfolio with the launch of AI-enabled multimodal immune profile algorithmic tests and the Tempus One clinical assistant, which leverages generative AI to provide clinicians with immediate patient insights [fERROR]Tempus AI Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through to 2026, focusing on leveraging its AI-driven precision medicine platform to introduce new and innovative healthcare solutions. The company plans to expand its portfolio with the launch of AI-enabled multimodal immune profile algorithmic tests and the Tempus One clinical assistant, which leverages generative AI to provide clinicians with immediate patient insights [fERROR][fERROR]Tempus AI Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through to 2026, focusing on leveraging its AI-driven precision medicine platform to introduce new and innovative healthcare solutions. The company plans to expand its portfolio with the launch of AI-enabled multimodal immune profile algorithmic tests and the Tempus One clinical assistant, which leverages generative AI to provide clinicians with immediate patient insights [fERROR][fERROR]. Additionally, Tempus AI aims to enhance its presence in the healthcare market by collaborating with pharmaceutical companies and researchers to develop personalized treatment options and optimize clinical trials [fERROR]Tempus AI Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through to 2026, focusing on leveraging its AI-driven precision medicine platform to introduce new and innovative healthcare solutions. The company plans to expand its portfolio with the launch of AI-enabled multimodal immune profile algorithmic tests and the Tempus One clinical assistant, which leverages generative AI to provide clinicians with immediate patient insights [fERROR][fERROR]. Additionally, Tempus AI aims to enhance its presence in the healthcare market by collaborating with pharmaceutical companies and researchers to develop personalized treatment options and optimize clinical trials [fERROR][fERROR]Tempus AI Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through to 2026, focusing on leveraging its AI-driven precision medicine platform to introduce new and innovative healthcare solutions. The company plans to expand its portfolio with the launch of AI-enabled multimodal immune profile algorithmic tests and the Tempus One clinical assistant, which leverages generative AI to provide clinicians with immediate patient insights [fERROR][fERROR]. Additionally, Tempus AI aims to enhance its presence in the healthcare market by collaborating with pharmaceutical companies and researchers to develop personalized treatment options and optimize clinical trials [fERROR][fERROR]. The company’s strategic initiatives also include expanding its data connections across healthcare institutions and continuing to amass one of the largest libraries of clinical and molecular oncology data in the world [fERROR]Tempus AI Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through to 2026, focusing on leveraging its AI-driven precision medicine platform to introduce new and innovative healthcare solutions. The company plans to expand its portfolio with the launch of AI-enabled multimodal immune profile algorithmic tests and the Tempus One clinical assistant, which leverages generative AI to provide clinicians with immediate patient insights [fERROR][fERROR]. Additionally, Tempus AI aims to enhance its presence in the healthcare market by collaborating with pharmaceutical companies and researchers to develop personalized treatment options and optimize clinical trials [fERROR][fERROR]. The company’s strategic initiatives also include expanding its data connections across healthcare institutions and continuing to amass one of the largest libraries of clinical and molecular oncology data in the world [fERROR]. These efforts are expected to drive significant growth, with forecasts indicating sales in excess of $500 million for 2023 and a future growth rate of over 20% [fERROR]Tempus AI Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through to 2026, focusing on leveraging its AI-driven precision medicine platform to introduce new and innovative healthcare solutions. The company plans to expand its portfolio with the launch of AI-enabled multimodal immune profile algorithmic tests and the Tempus One clinical assistant, which leverages generative AI to provide clinicians with immediate patient insights [fERROR][fERROR]. Additionally, Tempus AI aims to enhance its presence in the healthcare market by collaborating with pharmaceutical companies and researchers to develop personalized treatment options and optimize clinical trials [fERROR][fERROR]. The company’s strategic initiatives also include expanding its data connections across healthcare institutions and continuing to amass one of the largest libraries of clinical and molecular oncology data in the world [fERROR]. These efforts are expected to drive significant growth, with forecasts indicating sales in excess of $500 million for 2023 and a future growth rate of over 20% [fERROR].